Bristol-Myers Squibb Company (BMY) Q4 2025 (USD): Adj. EPS 1.26 (exp. 1.23), Revenue 12.5bln (exp. 12.28bln)

Bristol-Myers Squibb's Q4 2025 results show an adjusted EPS above expectations, albeit with a negative adjustment due to IPR&D charges.

Newsquawk StaffPublished On the live feed at 6 more headlines followed before this page went public
Newsquawk headlinesUTC

BoE Forecasts (Feb.): Lowers inflation forecasts across horizon, lowers GDP forecast for Q1 26 and Q1 27

STATEMENT: BoE holds rates at 3.75%, as expected; vote split 5-4 (exp. 7-2; Breeden, Dhingra, Taylor, Ramsden vote for cut to 3.5%)

Bristol-Myers Squibb Company (BMY) Q4 2025 (USD): Adj. EPS 1.26 (exp. 1.23), Revenue 12.5bln (exp. 12.28bln)

Ukrainian official's aide says Ukraine and Russia talks in Abu Dhabi have ended

KKR & Co Inc (KKR) Q4 2025 (USD): Diluted EPS 1.16 (exp. 1.16), Revenue 5.74bln; AUM +17% to USD 744bln

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • Adj. EPS includes net impact of -0.60 due to acquired IPR&D charges and licensing income.

Guidance:

  • 2026 revenue 46-47.5bln (exp. 44.16bln).
  • 2026 adj. EPS 6.05-6.35 (exp. 6.02).
Context

The positive guidance for 2026 revenue and EPS also surpasses market expectations, suggesting strong growth prospects that could influence sentiment in the pharmaceuticals sector and broader equities market.

Related headlines

The whole workspace, free to try.

Try it free